An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer

NCT00247676 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Neoplasms
Unresectable Hepatocellular Carcinoma

Interventions

DRUG: Sunitinib (SU011248)

Sponsor

Pfizer